Nebulizer vs Inhaler for COPD
Compare the Effects of Nebulizer Versus Inhaler Based Therapy for COPD Using Long-acting Bronchodilators
Recruiting
Phase 4
Interventional Study
COPD (Chronic Obstructive Pulmonary Disease)
No Placebo Group
Every participant receives an active treatment — no one gets a placebo.
Prior Safety Data
This treatment has already been tested in at least one earlier human trial.
At a Glance
- Age
- 40 and older
- Sex
- Any
- Trial phase
- Phase 4
- Study type
- Interventional
- Purpose
- Treatment
- Participants needed
- 72 (estimated)
- Sponsor
- University of Tennessee Graduate School of Medicine · Other
Who this trial is looking for
This trial is looking for people with COPD to compare two ways of taking medication. Participants will use either a nebulizer or an inhaler to see which method is more effective in improving their symptoms.
Are You a Good Fit for This Trial?
You may be able to join if
- I am over 40 years old.
- I have symptoms of COPD.
- I am a current or former smoker with more than 10 pack-years.
- I have a PIFR of over 30.
- I have airflow obstruction with a ratio of FEV1/FVC under 70%.
- I have significant air trapping with a residual volume over 120%.
You may not be able to join if
- I have asthma.
- I have had a heart attack in the past 12 weeks.
- I have been hospitalized for heart failure recently.
- I had an acute COPD flare-up in the past 8 weeks.
- I have uncontrolled glaucoma.
- I cannot give informed consent.
- I am currently pregnant or breastfeeding.
- I am already in a pulmonary rehabilitation program.
Summarized in plain language from this trial's official eligibility criteria. The full criteria are further down this page — only the research team can confirm whether you qualify.
Think this trial could be right for you?
Answer three quick questions written from this study's own rules to see if you may qualify. No account needed to find out.
Check Your Eligibility
About This Trial
The purpose of this study is to compare the effectiveness of inhaled bronchodilators delivered via nebulizers vs. dry powder inhalers (DPIs) in symptomatic participants with Chronic Obstructive Pulmonary Disease (COPD) who have airflow obstruction (FEV1/FVC ≤ 70%) and show significant air trapping (RV ≥ 120% of predicted).
The investigators hypothesize that, in patients with symptomatic COPD, the…
Trial Locations
Loading…
Loading trial locations…
Eligibility Criteria
Inclusion Criteria:
1. Age \> 40 years
2. Either sex
3. Current smoker or past cigarette smoking history of \> 10 pack-years
4. Symptoms of COPD (cough, sputum production, shortness of breath)
5. Modified Medical Research Council Dyspnea Scale (mMRC) score ≥2 or CAT score ≥10 at Screening/Run-in vi…
Contacts
No contact information available.